Cost-effectiveness analysis of multiple sclerosis treatment approaches

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68407700%3A21460%2F24%3A00371587" target="_blank" >RIV/68407700:21460/24:00371587 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.1007/978-3-031-62520-6_9" target="_blank" >https://doi.org/10.1007/978-3-031-62520-6_9</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/978-3-031-62520-6_9" target="_blank" >10.1007/978-3-031-62520-6_9</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Cost-effectiveness analysis of multiple sclerosis treatment approaches

Popis výsledku v původním jazyce

Multiple sclerosis is associated with significant impacts on both the patient's quality of life and the healthcare payer's budget. The therapy of multiple sclerosis is mainly implemented by the administration of expensive immunomodulatory drugs. The aim of this study is to evaluate the cost-effectiveness of two approaches in the treatment of multiple sclerosis in adult patients, comparing SC glatiramer acetate 40 mg and SC interferon beta-1a 44 μg from the perspective of a healthcare payer. The cost-effectiveness analysis was calculated based on effects identified by multicriteria decision making and direct costs from a healthcare payer perspective. Validation of the results was ensured by one-way sensitivity analysis. For the evaluated intervention SC glatiramer acetate 40 mg, the costs are CZK 176,933 and the effects are 0.24. For SC interferon beta-1a 44 μg, the costs are CZK 175,863 and the effects are 0.76. The resulting ICER was evaluated at -2,229 CZK, suggesting cost ineffectiveness of SC glatiramer acetate 40 mg compared with the comparator SC interferon beta-1a 44 μg.

Název v anglickém jazyce

Cost-effectiveness analysis of multiple sclerosis treatment approaches

Popis výsledku anglicky

Multiple sclerosis is associated with significant impacts on both the patient's quality of life and the healthcare payer's budget. The therapy of multiple sclerosis is mainly implemented by the administration of expensive immunomodulatory drugs. The aim of this study is to evaluate the cost-effectiveness of two approaches in the treatment of multiple sclerosis in adult patients, comparing SC glatiramer acetate 40 mg and SC interferon beta-1a 44 μg from the perspective of a healthcare payer. The cost-effectiveness analysis was calculated based on effects identified by multicriteria decision making and direct costs from a healthcare payer perspective. Validation of the results was ensured by one-way sensitivity analysis. For the evaluated intervention SC glatiramer acetate 40 mg, the costs are CZK 176,933 and the effects are 0.24. For SC interferon beta-1a 44 μg, the costs are CZK 175,863 and the effects are 0.76. The resulting ICER was evaluated at -2,229 CZK, suggesting cost ineffectiveness of SC glatiramer acetate 40 mg compared with the comparator SC interferon beta-1a 44 μg.

Druh

D - Stať ve sborníku

CEP obor

—

OECD FORD obor

50602 - Public administration

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název statě ve sborníku

Advances in Digital Health and Medical Bioengineering, Proceedings of the 11th International Conference on E-Health and Bioengineering, EHB-2023, November 9–10, 2023, Bucharest, Romania – Volume 2: Health Technology Assessment, Biomedical Signal Processing, Medicine and Informatics

ISBN

978-3-031-62519-0

ISSN

1680-0737

e-ISSN

1433-9277

Počet stran výsledku

9

Strana od-do

69-77

Název nakladatele

Springer Nature Switzerland AG

Místo vydání

Basel

Místo konání akce

Bucuresti

Datum konání akce

9. 11. 2023

Typ akce podle státní příslušnosti

WRD - Celosvětová akce

Kód UT WoS článku

001326809000009